Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients

Am J Kidney Dis. 2001 Aug;38(2):286-95. doi: 10.1053/ajkd.2001.26092.

Abstract

T-helper (Th) lymphocytes consist of Th1 and Th2 subsets. Th1 cells are effectors of cell-mediated immunity and secrete interferon-gamma (IFN-gamma), which recruits new Th1 cells in cooperation with interleukin-12 (IL-12; produced by monocytes) and inhibits Th2 differentiation. Th2 cells produce IL-4 and IL-10, which inhibit IFN-gamma secretion and cell immunity. We investigated whether the impaired immune response in uremia is associated with an altered balance of Th1/Th2. Peripheral-blood mononuclear cells (PBMCs) were collected from patients with chronic renal failure (CRF) on conservative treatment (CRF patients), patients with end-stage renal disease (ESRD) on regular hemodialysis therapy (ESRD-HD patients), and healthy controls (CON). CD4(+) cells were isolated from PBMCs by negative selection using a magnetic labeling system. PBMCs and purified CD4(+) cells were cultured in Iscove's medium and Iscove's medium plus mitogens (phytohemagglutinin and lipopolysaccharide). IFN-gamma, IL-12, IL-4, and IL-10 were measured in supernatant. The constitutive release of IL-4 and IL-10 by PBMCs and CD4(+) cells of CRF and ESRD-HD patients was increased by five to eight times in comparison with CON (P < 0.001). Constitutive IFN-gamma release by PBMCs of ESRD-HD patients was undetectable, although they secreted an increased amount of IL-12. Mitogen-stimulated release of IFN-gamma by PBMCs and CD4(+) cells of CRF and ESRD-HD patients was blunted (average PBMCs: CON, 115.8 pg/2 x10(6) cells; CRF, 81.8 pg/2 x10(6) cells; ESRD-HD, 9.3 pg/2 x10(6) cells; CD4(+) cells: CON, 358.0 pg/5 x 10(5) cells; CRF, 165.4 pg/5 x 10(5) cells; ESRD-HD, 43.5 pg/5 x 10(5) cells). The ability of PBMCs of ESRD-HD patients to secrete IFN-gamma was recovered after IL-4 and IL-10 neutralization. Uremia is associated with a prevalence of Th1 over Th2 cells and a configuration of cytokine network that depresses cell-mediated immunity.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • CD4-Positive T-Lymphocytes / immunology*
  • Cytokines / analysis
  • Female
  • Humans
  • Immunity, Cellular / immunology
  • Interferon-gamma / analysis
  • Interleukin-10 / analysis*
  • Interleukin-4 / analysis*
  • Kidney Failure, Chronic / immunology*
  • Kidney Failure, Chronic / therapy
  • Leukocytes, Mononuclear / immunology
  • Male
  • Middle Aged
  • Phenotype
  • Renal Dialysis
  • Th1 Cells / immunology*
  • Th2 Cells / immunology*

Substances

  • Cytokines
  • Interleukin-10
  • Interleukin-4
  • Interferon-gamma